Remicade OK'd for spinal arthritis on same day warning issued

12/21/2004 | Wall Street Journal, The

On the same day Johnson & Johnson's Centocor unit announced FDA approval of Remicade for treating a form of spinal arthritis, the parent company issued a warning the drug could be associated with an increased risk of liver failure and pneumonia. The drug previously was indicated only for treating Crohn's disease and rheumatoid arthritis, injected during a visit to a clinic. Centocor said there was no proof in the trials Remicade caused the liver damage detected in three patients on the drug, but the label is to be changed to warn of such possible damage, plus an increased risk of pneumonia.

View Full Article in:

Wall Street Journal, The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
MGR POST MARKET STUDIES - 14000001LK
Abbott
Santa Ana, CA
Regulatory Analyst
Delta Dental
Alpharetta, GA
Eastern Zone Sales Director
Regenesis Biomedical
Multiple Locations, SL_Multiple Locations
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA
Associate Director, Regulatory Affairs - Promotional Review
Novo Nordisk
Princeton, NJ